Kornimate/medical-research-clean huggingface dataset:
a study to evaluate awareness and knowledge of the fibristal additional risk minimization measures among healthcare professionals in canada

Conditions: Uterine Fibroids

Summary: this is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the additional risk minimization measures for fibristal among healthcare professionals (hcps).

data will be collected via web-based data capture by hcps submitting surveys. the survey will be conducted in a single wave over 6 months. all data will be maintained in compliance with local regulations.

Eligibility criteria:
inclusion criteria: * hcps have prescribed fibristal for the indication of uterine fibroids within the past 6 months. * hcps have provided permission to share their responses in aggregate to health canada. exclusion criteria: * hcps who participated in the cognitive pre-testing of the survey questionnaire to be used for the study. * hcps who have been direct employees of allergan, icon, health canada, or professional targeted marketing (ptm) within the past 5 years.
effects of prednisolone on rheumatoid arthritis patients

Conditions: Arthritis, Rheumatoid

Summary: this study will assess the pharmacokinetic (pk) and pharmacodynamic (pd) effects of prednisolone on rheumatoid arthritis (ra) patients.


Eligibility criteria:
inclusion criteria: * meet the acr criteria for diagnosis of rheumatoid arthritis. * required treatment with prednisolone. * currently on a non-steroidal anti-inflammatory agent (nsaid). * willing to stay on current dose of nsaid for two weeks during study. exclusion criteria: * major health issues such as osteoporosis, diabetes, heart failure, heart attack, kidney failure, or acute infection.

Keywords: rheumatoid arthritis
effect of high dose insulin on infectious complications following major surgery

Conditions: Surgical Site Infection After Major Surgery

Summary: despite improvements in surgical techniques and perioperative care, the high incidence of postoperative surgical site infections remains a major problem in patients undergoing major abdominal surgery (liver, pancreatic and colorectal surgery). using the hyperinsulinemic-normoglycemic clamp technique, i.e. continuous infusion of insulin combined with dextrose titrated to "clamp" blood glucose between 4 and 6 mmol/l, we successfully established and preserved normoglycemia during the perioperative period. our objective of this study is to determine if the maintenance of perioperative normoglycemia by a hyperinsulinemic normoglycemic clamp reduces the rates of incisional and space/ surgical site infections following abdominal surgery (liver, pancreatic and colorectal surgery).

this randomized, open-label, controlled trial will be performed in adult (\>18 years old) patients scheduled for elective open abdominal aortic aneurysm repairs and open hepatobiliary procedures including liver resections, pancreatectomies, duodenectomies, gastrojejunostomies, choledochojejunostomies and hepaticojejunostomies) at the royal victoria hospital (rvh), mcgill university health centre (muhc), montreal, qc, canada. inclusion criteria: above 18 years old, scheduled for elective open abdominal aortic aneurysm repairs and open hepatobiliary procedures. exclusion criteria: inability to give consent, current wound infection, previous surgery at the same site within the preceding 30 days, allergy to insulin. recruitment initial contact prior to surgery will be made by a research team member not involved in the care of the patient who will explain the research project and obtain written consent. consenting patients will then be randomized with the assistance of a computerized randomization system.

Eligibility criteria:
inclusion criteria: * \> 18 years old * elective liver, pancreatic or colorectal surgery * ability to give informed consent exclusion criteria:

Keywords: insulin, surgery, infection
opioid sparing analgesia: dexmedetomidine versus lidocaine for intracranial surgeries in children

Conditions: Analgesia

Summary: perioperative pain control is necessary in children as inadequate treatment may lead to progression of perception of pain and development of chronic pain in the future. anesthetists tend to adopt approach to perioperative control of pain by non-opioid drugs that mediate pain modulation. its use as opioid sparing analgesia in different surgeries leading to mixed results.

site of study: this study will be carried out in neurosurgical operating rooms of zagazig university hospitals. b. sample size: a pilot study was done to estimate percent of children need intraoperative fentanyl was (10%) for dexmedetomidine group, and ( 40%) for lidocaine group, at 0.05 α error and 0.2 β error . sample size was calculated using open epi software, is 32 children in each group.

Eligibility criteria:
inclusion criteria: * age: 6-18 years old. * sex: both sexes. * physical status: american society of anesthesiologist 1\& ii. * body mass index \>5 th and \< the 85th percentile for age. * type of operations: elective intracranial surgeries under general anesthesia. * duration of operation \< 3 hours. * written informed consent from the parent of child exclusion criteria: * altered mental state * unsuitability for extubation. * patients on beta blocker, alpha 2 agonist. * patients on pain killer or with known history of allergy to study drugs. * hepatic, renal, cardiovascular and respiratory disease. * the patient has the right to withdraw from the study at any time without any negative consequence on their medical or surgical treatment plan.
finnish geriatric intervention study to prevent cognitive impairment and disability

Conditions: Cognitive Impairment; Dementia

Summary: this multi-center (6 sites: helsinki, kuopio, oulu, seinäjoki, turku, vantaa) intervention study aims to prevent cognitive impairment, dementia and disability in 60-77 year old persons at an increased dementia risk. the 2-year multi-domain life-style intervention includes nutritional guidance, exercise, cognitive training, increased social activity, and intensive monitoring and management of metabolic and vascular risk factors. the primary outcome is cognitive impairment measured by a sensitive neuropsychological test battery (ntb), and stroop and trail making tests to capture early cognitive impairment typical for both alzheimer's disease and vascular dementia. we hypothesize that the multi-domain intervention will reduce cognitive impairment in the study group compared to the control group during the initial 2-year intervention period and reduce dementia incidence after the extended follow-up (until at least 300 participants have developed dementia).


Eligibility criteria:
inclusion criteria: * aged 60-77 years * dementia risk score 6 points or more * fulfillment of at least one of the following cerad criteria: i) mmse: 20-26 points ii) word list memory task (3x10 words): 19 words or less iii) delayed recall: 75% or less exclusion criteria: * malignant diseases * dementia * substantial cognitive decline * major depression * symptomatic cardiovascular disease * revascularisation within 1 year * severe loss of vision, hearing or communicative ability * other conditions inhibiting from safe engagement in the prescribed intervention as judged by the study physician * other conditions preventing from cooperation as judged by the study physician

Keywords: dementia cognitive impairment disability intervention elderly lifestyle counseling
advanced adenoma detection with 3d imaging device during colonoscopy

Conditions: Colorectal Adenoma; Colorectal Polyps

Summary: the goal of this clinical trial is to learn if 3-dimensional (3d) imaging device works to identify patients with high risk adenomas during colonoscopy to guide proper follow-up strategy. it will also learn about the safety of 3-dimensional (3d) imaging device. the main questions it aims to answer are: does 3-dimensional (3d) imaging device improve the identification of patients with high risk adenomas? what adverse events do participants experience during colonoscopy? researchers will compare 3-dimensional (3d) imaging device to traditional 2-dimensional (2d) imaging device to see if 3-dimensional (3d) imaging device works to improve high risk adenoma identification. participants will: undertake colonoscopy examination using 3-dimensional (3d) imaging device or 2-dimensional (2d) imaging device. be followed-up to 30 days to record potential colonoscopy-relevant adverse events.


Eligibility criteria:
inclusion criteria: * aged 18-75 years; * patients with indications for colonoscopy and receiving diagnostic colonoscopy, without history of inflammatory bowel disease, colorectal cancer, polypectomy or polyposis syndromes; * signing the written informed consent; exclusion criteria: * patients with polyposis syndromes (e.g., peutz-jeghers syndrome, cronkhite-canada syndrome, familial adenomatous polyposis \[fap\], lynch syndrome, etc.); * patients with a history of colorectal polypectomy and pathological diagnosed as adenoma; * patients with a history of colorectal adenocarcinoma or alarming symptoms; * patients with a history of inflammatory bowel disease; * patients with mental illness or severe functional disorder who cannot cooperate with colonoscopy; * patients with severe cardiopulmonary insufficiency; * patients with severe coagulation disorders or high bleeding risk (platelets \ 1.5; discontinuation of antithrombotic drugs should follow the 2012 japanese guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment and the2017 appendix on anticoagulants including direct oral anticoagulants; * patients with severe electrolyte imbalances; * patients with acute peritonitis or suspected intestinal perforation; * patients with toxic megacolon; * patients with stage 3 or higher hypertension (systolic blood pressure ≥180 mmhg or diastolic blood pressure ≥110 mmhg); * patients with untreated severe abdominal hernia, intestinal obstruction; * patients with intestinal strictures of any cause; * pregnancy and lactation.
goal directed therapy after aneurysmal subarachnoid haemorrhage

Conditions: Aneurysmal Subarachnoid Haemorrhage; SAH

Summary: the objective of this study is to determine whether a goal-directed therapy can reduce the incidence of delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage.

the aneurysmal subarachnoid haemorrhage (sah) is a frequent and dangerous worldwide cause for stroke. a typical complication presents delayed cerebral ischemia as a consequence of cerebral vasospasms, which occurs in 46% of the cases. the triple-h-therapy (hypervolaemia, hypertension and haemodilution) was favoured to prevent ischaemic complications after vasospasm for a long time. however recently, the focus is mainly on hypertension, and it is recommended to maintain normovolaemia. the debate how to assure normovolaemia is still on going, therefore, this study was designed to examine whether a picco-controlled haemodynamic monitoring and a goal-directed therapy can reduce the incidence of delayed cerebral ischaemia after sah. the present study is a prospective randomized controlled clinical study. patients older than 18 years with an aneurysmal sah will be enrolled. they will be divided into two groups: a control group "c" and a picco group "p". both groups will be treated according to the current guidelines. in addition, in group p the volume and catecholamine therapy will be controlled by means of picco-controlled monitoring and an algorithm. the primary end point is the number of occurred delayed cerebral ischaemia per patient. secondary end points are neurological, pulmonary, cardiovascular, renal, and hepatic complications as well as electrolyte and serum glucose disturbance, sepsis, and mortality, length of hospital and intensive care unit stay and the amount of volume and catecholamines administered. all participants are to be contacted three months after discharge, and their health status is to be determined by using the gos (glasgow outcome scale).

Eligibility criteria:
inclusion criteria: * aneurysmal subarachnoid haemorrhage (sah) * age ≥ 18 years exclusion criteria: * traumatic sah * congestive heart failure * severe diseases of aorta or aortic valve * pregnancy * calcium antagonist intolerance

Keywords: subarachnoid haemorrhage (sah) vasospasm delayed cerebral ischaemia (dci) goal directed therapy (gdt) pulse contour cardiac output (picco)
m. hailey-hailey: hspca1 expression and skin structure upon laser therapy

Conditions: Hailey Hailey Disease

Summary: hailey-hailey disease is a genetic acantholytic dermatosis characterized by continuous erosion of the skin that results in a burning, painful sensation and restricts the patient in daily life. this disorder results from a genetic defect in a calcium pump, i.e. the hspca1 pump. calcium pumps are crucial for the processing of cell-cell adhesion proteins such as e-cadherin, part of desmosomes, the major glue between keratinocytes in skin epidermis. today therapy is mainly focussed on symptom relief and prevention of secondary infection. ablative laser therapy is known to result in a speedy healing of the affected skin site within 2 weeks following laser therapy. the fact that the treated skin site remains clear from this acantholytic disorder in the months/years following ablation, regardless the existence of a germline mutation, suggests that an epigenetic modification occurs in the process of wound healing. objective: to (1) study the expression of hspca1 in keratinocytes before and after laser therapy and (2) verify the loss of acantholysis by immunohistochemistry and electron microscopy of cell-cell adhesions before and after laser therapy


Eligibility criteria:
1.inclusion criteria 1.1.hailey-hailey patients inclusion criteria: * clinically diagnosed m. hailey-hailey as confirmed by histopathology and/or genetic analysis. * indication for ablative laser therapy * \>18 years old * informed consent 1.2. patients without hailey-hailey disease * \>18 years old * clinically no symptoms of m. hailey-hailey * informed consent exclusion criteria: * \<18 years old * treatment with tetracyclines, topical hormones or oral retinoids within the last 30 days preceding participation * lack of informed consent
the effect of combination of vitamin a, vitamin e, sodium hyaluronate 0.15% eye drop compared with sodium hyaluronate 0.1% eye drop to tear film stability and conjunctival goblet cells density in patient with non-proliferative diabetic retinopathy (npdr), and proliferative diabetic retinopathy (pdr)

Conditions: Non-Proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy New Vessels on Disc; Dry Eye Syndromes

Summary: commonly know that one of the complications caused by diabetes mellitus (dm) is microangiopathy. microangiopathy in the long term may lead to neuropathy of the corneal nerves. neuropathy of the cornea will lead to dry eyes in dm patient. one of the artificial tears used in treating dry eyes is sodium hyaluronate. but until recently no research had been done in examining the effect of giving combination of sodium hyaluronate, vitamin a and vitamin e in dry eyes. the antioxidant, and capability of vitamin a and e in promoting cell proliferation may alleviate the symptoms of dry eyes. in this paper we used ocular surface disease index (osdi), tear break up time, schirmer i test and impression cytology to assess baseline and 28 days post therapy in patient with non-proliferative diabetic retinopathy (npdr), and proliferative diabetic retinopathy (pdr)

the study is double blind randomized clinical trial, comparing the usage of combination of sodium hyaluronate 0.15%, vitamin a and vitamin e eye drops compared to sodium hyaluronate 0.1% eye drop only in patient with npdr or pdr with decreased corneal sensitivity. the examination consisted of osdi questionnaire, tear film break up time, schirmer i, and goblet cell density, examined at baseline and 4 weeks (day 28) after the initial eye drops is given. for sample size calculation, estimated 96 patients are required to give statistical effect, this number already calculating the possibility of 20% drop out rate. every eligible patient is then randomized with block randomization into each allocated arm. statistical analysis used for this study is unpaired t test if the data distribution is normal, if not mann-whitney test will be used.

Eligibility criteria:
inclusion criteria: * dm patients with npdr or pdr * corneal sensitivity less than 45 mm with cochet bonnet esthesiometer exclusion criteria: * patient with anterior chamber inflammation * patient with history of ocular surgery (ex. repair of corneal rupture, cataract surgery, lasik) * patient with history of cerebrovascular event that may affect cognitive function * patient had event of disease which may impact corneal sensitivity (ex. viral keratitis, ophthalmic herpes zoster) * patient with corneal cicatrix * patient on anti-allergic medication * pregnant or lactating woman

Keywords: diabetes mellitus proliferative diabetic retinopathy non-proliferative diabetic retinopathy dry eye syndromes sodium hyaluronate vitamin a vitamin e
effects of a mobile app-based mindfulness intervention in persons with spinal cord injury and chronic pain

Conditions: Spinal Cord Injuries

Summary: the purpose of this study is to evaluate the efficacy of a 6-week app-guided mm intervention compared to a 6-week app-guided health education ac condition on pain intensity, pain interference, depression, and anxiety.


Eligibility criteria:
inclusion criteria: * traumatic sci of at least 6 months duration * chronic pain \[defined as pain lasting at least 3 months with a pain intensity rating of 4 or higher on a 10-point visual analog scale\] * understand spoken and written english sufficiently to provide informed consent, participate in the intervention and complete study surveys exclusion criteria: * lack of daily internet access * inability to demonstrate comprehension of informed consent by correctly answering 4 out of 5 questions about the study * significant visual/hearing impairment that does not allow use of the mm app's audiovisual presentations * use of any meditation more than once a week in the last 3 months * inability to provide or obtain an email address for registration to the ac intervention and/or communication with study staff * inability to provide a phone number for communication with study staff
collaborative assessment of icu recovery needs

Conditions: Post-Intensive Care Syndrome

Summary: the primary purpose of this study is to better understand the impact of the society of critical care medicine (sccm) thrive collaboratives on patients, their families and clinicians. the investigators have formed an international and interprofessional evaluative team with experts in the field in an effort to explore interactions between survivors and thrive. this approach is reflective of the international ethos of sccm and its collaboratives, with the potential to improve the generalizability of this survivorship research to different health systems.

the aims of this qualitative study are: 1. to identify elements that helped survivors in their recovery, as well as potential obstacles 2. to capture elements of survivorshop that are generalizable, regardless of participation in the thrive collaboratives 3. to gain knowledge to be incorporated back into the collaboratives patients, family members, and clinicians will be interviewed and their responses analyzed for themes of icu recovery including elements that patients and families find helpful to recovery, barriers and facilitators to different models of post-icu support, including peer support and post-icu clinics, and drivers of improvement in post-icu care. patients, carers, and clinicians with a wide variety of survivorship experiences are encouraged to participate, including those who have participated in a thrive collaborative support site (peer support or clinic).

Eligibility criteria:
inclusion criteria: 1. patients who survived a critical illness, and their carers, who were identified by collaborative members or self-identify as having been through a thrive program. 2. patients who survived a critical illness, and their carers, who did not participate in a thrive program. 3. clinicians directly involved in the care of icu survivors in the outpatient setting, who have participated in a thrive initiative through the society of critical care medicine. exclusion criteria: * n/a

Keywords: icu delirium post-intensive care syndrome critical illness myopathy
repetitive transcranial magnetic stimulation

Conditions: Schizophrenia

Summary: the study is a prospective, randomized, double-blind sham-controlled study.

the principal objective of this trial is to investigate the effect of left prefrontal high frequency rtms on negative symptoms in schizophrenia.

Eligibility criteria:
inclusion criteria: * dsm-iv criteria for schizophrenia * age between 18 and 60 * informed consent * right handed patient * no change of antipsychotic treatment \> 2 weeks before recruitment exclusion criteria: * seizures, epilepsy * history of severe head injury * status post implantation of a cardiac pacemaker or other electronic devi-ses

Keywords: schizophrenia, rtms
evaluation of oxygen diffusion dressing for accelerating healing of donor site and other wounds

Conditions: Burns

Summary: this is a single-center, prospective, randomized, and controlled study to evaluate the effectiveness of oxyband dressing for the use as a dressing for autogenous skin donor sites compared to our current standard donor site dressing (xeroform). hypothesis is that the mean healing time for wounds treated with the oxyband dressing will be less than the mean healing time for wounds treated with the xeroform dressing.

patients who are scheduled for excision of burns or other injuries will have one of two donor sites covered with the oxyband dressing, and the other treated according to standard of care. oxyband is an fda (food and drug administration) approved (k043063) wound dressing for delivery of oxygen into the wound. two small clinical studies using oxyband have been conducted on standardized laser burn wounds, demonstrating faster healing time compared to a placebo. no studies have compared this dressing to xeroform dressing, the standard dressing used on donor sites in the usaisr.

Eligibility criteria:
inclusion criteria: * subject must be at least 18 years of age; of either gender and in good general health. * subject has sustained burn wounds of less than 30 percent of the total body surface area * burn wounds do not involve the harvesting area * subject has sustained burn wounds that, in the judgment of the attending surgeon, require excision and grafting of sufficient extent to justify two donor sites of equal and symmetrical size on non-dependent body surfaces areas * the scheduled excision and grafting procedure is the first such operation for the subject during this hospitalization * subject agrees to participate in follow-up evaluations exclusion criteria: * critical illnesses such as those requiring ventilator support, or having a systemic infection or hemodynamic instability, defined as a mean arterial pressure less than 60 or requiring vasoactive medications to support blood pressure * major acute or chronic medical illnesses that could affect wound healing (e.g. peripheral vascular disease, insulin dependent diabetes, blood clotting disorder) * subjects receiving treatment with medications that inhibit or compromise wound healing. examples include therapeutic anticoagulants, antiplatelet drugs, and systemic steroids such as warfarin, clopidogrel or prednisone. the use of anticoagulants does not include dvt (deep vein thrombosis) prophylaxis. subjects may use aspirin or lovenox * cellulitis or other infection of the potential donor sites * donor site has been previously harvested for grafting * subjects with greater than 30% total body surface area burns * pregnancy * prisoners

Keywords: burn wound management with oxygen